Current Location:Home > Digital Entertainment Insights > Main Content

Patents Involving EG333: Key Innovations and Commercial Applications

photo_2025-04-14_12-17-22.jpgIntroduction to EG333 in Patent Literature

The chemical compound EG333 has been the subject of numerous patent filings across multiple industries, reflecting its commercial potential and technological value. From pharmaceutical formulations to industrial processes, these patents reveal how innovators are leveraging EG333's unique properties.

This comprehensive analysis explores:

  • Major patent categories involving EG333

  • Key technological breakthroughs

  • Leading companies and research institutions in EG333 innovation

  • Future patent trends and opportunities

Breakdown of EG333 Patent Categories

1. Pharmaceutical and Medical Applications

EG333 has inspired numerous healthcare-related patents:

A. Drug Formulation Patents

  • USPTO #US20180214456A1: "Extended-release formulations using EG333 derivatives"

  • EP3287114B1: "EG333 as a bioavailability enhancer for poorly soluble drugs"

B. Therapeutic Use Patents

  • WO2020159872A1: "EG333 analogs for neurodegenerative disease treatment"

  • CN107847689B: "Topical compositions containing EG333 for dermatological conditions"

Notable Assignee: Novartis AG's 2022 patent portfolio includes 3 EG333-related drug delivery systems

2. Industrial and Material Science Innovations

Manufacturing patents demonstrate EG333's versatility:

A. Polymer Technology

  • US10494472B2: "EG333-modified polymers with enhanced thermal stability"

  • JP2019535847A: "Crosslinking agent compositions containing EG333"

B. Specialty Chemicals

  • KR102345678B1: "EG333-based corrosion inhibitors for marine applications"

  • DE102017009528B4: "Lubricant additives incorporating EG333 nanoparticles"

3. Agricultural Formulations

Emerging applications in agrochemicals:

  • AU2018344128B2: "EG333-containing pesticide synergists"

  • BR112020005827A2: "Slow-release fertilizer compositions using EG333"

Geographic Distribution of EG333 Patents

An analysis of filing jurisdictions reveals:

  • United States: 42% of total filings (2015-2023)

  • European Patent Office: 28%

  • China: 15% (showing rapid growth since 2018)

  • Other jurisdictions: 15%

Key Patent Holders and Innovators

Leading organizations in EG333 IP development:

  1. BASF SE (Germany): 17 active patents in material science applications

  2. Merck KGaA (Germany): 12 patents in pharmaceutical uses

  3. Dow Chemical (USA): 9 patents in industrial formulations

  4. Sinochem Group (China): 7 recent filings in agricultural uses

Emerging Patent Trends (2023-2024)

Recent filings indicate new directions:

  • Green chemistry applications: EP4122899A1 (biodegradable EG333 variants)

  • Energy storage: US20230366027A1 (battery electrolyte additives)

  • Cosmeceuticals: WO2023187687A1 (anti-aging formulations)

Patent Challenges and Legal Considerations

Important IP aspects for potential users:

  • Freedom-to-operate analyses required due to dense patent landscape

  • Formulation patents often more valuable than composition-of-matter claims

  • Regional differences in patent protection strategies

Future Outlook for EG333 Patents

Projected growth areas:

  1. Biopharmaceutical conjugates (anticipated 2024-2025 filings)

  2. Advanced material composites (particularly for electronics)

  3. Sustainable chemical processes (circular economy applications)

Conclusion: The Evolving EG333 Patent Landscape

The expanding portfolio of EG333-related patents demonstrates its growing importance across multiple industries. For companies considering EG333 applications:

  • Conduct thorough prior art searches

  • Monitor competitor patent activity

  • Consider alternative formulations to navigate crowded spaces